Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.
Results 1 to 1 of 1
MEDiscuss • Medical News • Transplant drug two-year study outcomes show superior kidney function
- May 6th, 2010 #1Bot
- Member since
- Jul 2007
- Posts
- 20,764
Transplant drug two-year study outcomes show superior kidney function
QuoteRelated Posts
-
Common invasive test not necessary for kidney disease patients, study finds; Clinicians can monitor kidney function with a simple equation
By MedBot in forum Medical NewsReplies: 0Last Post: September 16th, 2011, 12:02 AM -
Genes, not race, determine donor kidney survival; Implications for kidney transplant recipients and kidney donors
By MedBot in forum Medical NewsReplies: 0Last Post: May 10th, 2011, 03:01 PM -
Metabolic syndrome in living kidney donors worsens function of remaining kidney, study finds
By MedBot in forum Medical NewsReplies: 0Last Post: June 21st, 2010, 03:00 PM -
Post-transplant drug may also help patients with common genetic kidney disease
By MedBot in forum Medical NewsReplies: 0Last Post: May 20th, 2010, 05:09 AM -
Cancer risk the same for kidney transplant recipients, no matter the drug, study finds
By MedBot in forum Medical NewsReplies: 0Last Post: May 4th, 2010, 04:03 AM
